Voyager Therapeutics (VYGR) EV to EBIT (2015 - 2026)

Voyager Therapeutics has disclosed EV to EBIT across 12 years of filings, most recently posting 3.72 for Q2 2026.

• In Q2 2026, EV to EBIT fell 415.26% year-over-year to 3.72; the TTM figure through Jun 2026 stood at 0.84 (down 339.21% YoY), while the FY2025 annual figure was 0.27, up 48.45% from the prior year.
• EV to EBIT came in at 3.72 for Q2 2026 at Voyager Therapeutics, down from 3.02 in the prior quarter.
• In the past five years, EV to EBIT ranged from a high of 6.68 in Q3 2022 to a low of 8.98 in Q2 2023.
• Average EV to EBIT over 5 years is 1.86, with a median of 2.3 recorded in 2023.
• Year-over-year, EV to EBIT surged 658.39% in 2022 and plunged 1408.8% in 2024.
• Over 5 years, EV to EBIT stood at 4.75 in 2022, then surged by 154.82% to 2.6 in 2023, then plunged by 143.75% to 1.14 in 2024, then fell by 4.41% to 1.19 in 2025, then plunged by 212.49% to 3.72 in 2026.
• Per Business Quant data, the three most recent EV to EBIT figures were 3.72 in Q2 2026, 3.02 in Q1 2026, and 1.19 in Q4 2025.